Nature Search

A benchmark of expert-level academic questions to assess AI capabilities

Humanity’s Last Exam, a multi-modal benchmark at the frontier of human knowledge, is designed to be an expert-level closed-ended academic benchmark with broad subject coverage.

Long Phan
Alice Gatti
Davide Scaramuzza
ResearchOpen Access28 Jan 2026
Nature

Volume: 649, P: 1139-1146
Contextualizing T_H17 cells in cancer

T helper 17 (T_H17) cells can have both pro-tumour and antitumour effects. Understanding how they are regulated by environmental and regulatory cues according to context will inform strategies to harness their activity for the development of next-generation cancer immunotherapies.

Declan Pang
Alice Bertocchi
Mathilde Pohin
Reviews06 Jan 2026
Nature Reviews Immunology

P: 1-15
What difference does a genome make?

The malaria parasite's genome should provide a wealth of new scientific opportunities. But this may heighten tensions over how best to spend the scant resources allocated to malaria research and control. Declan Butler reports.

Declan Butler
News03 Oct 2002
Nature

Volume: 419, P: 426-428
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression

miRNAs can function either as proto-oncogenes or tumour suppressors in several cancers; however their function in tumour initiating cells is unclear. Here, Zhang et al. show that tumour initiating cell-specific miR-1246 and miR-1290 promote lung cancer initiation and metastasis and could serve as prognostic markers.

Wen Cai Zhang
Tan Min Chin
Bing Lim
ResearchOpen Access21 Jun 2016
Nature Communications

Volume: 7, P: 1-16
SARS-CoV-2 evolution during treatment of chronic infection

Chronic infection with SARS-CoV-2 leads to the emergence of viral variants that show reduced susceptibility to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma.

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Research05 Feb 2021
Nature

Volume: 592, P: 277-282
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Sera from vaccinated individuals and some monoclonal antibodies show a modest reduction in neutralizing activity against the B.1.1.7 variant of SARS-CoV-2; but the E484K substitution leads to a considerable loss of neutralizing activity.

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Research11 Mar 2021
Nature

Volume: 593, P: 136-141
Genomic reconstruction of the SARS-CoV-2 epidemic in England

A study of the evolution of the SARS-CoV-2 virus in England between September 2020 and June 2021 finds that interventions capable of containing previous variants were insufficient to stop the more transmissible Alpha and Delta variants.

Harald S. Vöhringer
Theo Sanderson
Moritz Gerstung
ResearchOpen Access14 Oct 2021
Nature

Volume: 600, P: 506-511
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E24
Author Correction: SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E23
Publisher Correction: Genomic reconstruction of the SARS CoV-2 epidemic in England

Harald S. Vöhringer
Theo Sanderson
Moritz Gerstung
Amendments and CorrectionsOpen Access07 Jun 2022
Nature

Volume: 606, P: E18
The single-cell opioid responses in the context of HIV (SCORCH) consortium

Seth A. Ament
Rianne R. Campbell
Hongkui Zeng
ReviewsOpen Access15 Jun 2024
Molecular Psychiatry

Volume: 29, P: 3950-3961

Search

Filter By:

Search

Quick links